2005-2001

2005

 

Gender difference in HIV-1 RNA viral loads.
Donnelly CA, Bartley LM, Ghani AC, Le Fevre AM, Kwong GP, Cowling BJ, van Sighem AI, de Wolf F, Rode RA, Anderson RM.
HIV Med. 2005 May;6(3):170-8.
Link naar publicatie

High prevalence of resistant HIV patients failing on HAART in the Netherlands.
de Wolf F, van Sighem, AI, Bezemer D, Back N, Schuurman R, Claas E, Schutten M, Jurriaans S, Osterhaus A, Kroes L, Boucher C.
Nederlands Tijdschrift voor Medische Microbiologie. 13 (Suppl): S65, 2005.

Mortality in patients with successful initial response to Highly Active Antiretroviral Therapy is still higher than in non-HIV-infected individuals.
van Sighem A, Danner S, Ghani AC, Gras L, Anderson RM, de Wolf F; on behalf of the ATHENA National Observational Cohort Study.
J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):212-218.
Link naar publicatie

Mortality rates according to initial HAART regimen: A collaborative analysis of 12 prospective cohort studies.
Hogg R, Lundgren J, Costagliola D, Monforte A, Ledergeber B, de Wolf F, Fusco G, Staszewski S, Chêne G, Phillips A, Gill J, Rockstroh J, May M, Sterne J, Egger M and ART Cohort Collaboration.
In CROI February 2005 12th conference on retroviruses and oppurtunistic infections, (Foundation for retrovirology and human health, Alexandria, VA, 2005), chap.589, p.269.

Nelfinavir and nevirapine side effects during pregnancy.
Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group.
AIDS. 2005 May 20;19(8): 795-9.
Link naar publicatie

Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data.
May M, Porter K, Sterne JA, Royston P, Egger M.
J Clin Epidemiol. 2005 Oct;58(10):1033-41.
Link naar publicatie

Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
Wit FW, Blanckenberg DH, Brinkman K, Prins JM, van der Ende ME, Schneider MM, Mulder JW, de Wolf F, Lange JM; on behalf of the ATHENA Study Group.
AIDS. 2005 Feb 18;19(3):345-8.
Link naar publicatie

Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data.
Xue H, Lam KF, Cowling BJ, de Wolf F. Department of Mathematics, Graduate University of Chinese Academy of Sciences, Beijing, China.
Stat Med. Dec 22, 2005.
Link naar publicatie

The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy
The Antiretroviral Therapy Cohort Collaboration: Antonella dÕArminio Monforte, MD, Caroline A. Sabin, PhD, Andrew Phillips, PhD, Jonathan Sterne, PhD, Margaret May, PhD, Amy Justice, PhD, Francois Dabis, PhD, Sophie Grabar, PhD, Bruno Ledergerber, PhD, Jo
Arch Intern Med. 2005;Feb 28;165:416-423
Link naar publicatie

The effect of low level transient HIV viremia on the outcome of HAART.
de Wolf F, van Valkengoed I, Gras L, Pogany K, Prins J, van Sighem A.
Tijdschrift voor Medische Microbiologie. 13 (Suppl): S85, 2005

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
Crommentuyn KM, Huitema AD, Brinkman K, van der Ende ME, de Wolf F, Beijnen JH; Athena study.
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):249-50.
Link naar publicatie

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD; EuroSIDA Study Group.
Antivir Ther. 2005;10(7):791-802.
Link naar publicatie

Treatment Interruption in Early Starters in the Netherlands (TRIESTAN): Successful for at Least 36 Weeks.
Pogány K, van Valkengoed I, Kroon F, Prins J, Lange J, Brinkman K.
In CROI February 2005 12th conference on retroviruses and oppurtunistic infections, (Foundation for retrovirology and human health, Alexandria, VA, 2005), chap.584, p.267.

Treatment Interruption in Early Starters in the Netherlands (TRIESTAN): Successful for at Least 36 Weeks.
Pogány K, van Valkengoed I, Kroon F, Prins J, Lange J, Brinkman K.
In CROI February 2005 12th conference on retroviruses and oppurtunistic infections, (Foundation for retrovirology and human health, Alexandria, VA, 2005), chap.584, p.267. 

 

2004

 

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group.
Antivir Ther. 2004 Oct;9(5):787-800.
Link naar publicatie

Cardio- and cerebrovascular events in HIV-infected persons.
d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N; Writing Committee of the D:A:D: Study Group.
AIDS. 2004 Sep 3;18(13):1811-7.
Link naar publicatie

Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J; EuroSIDA study group.
AIDS. 2004 Nov 19;18(17):2333-7.
Link naar publicatie

Declining trend in transmission of drug-resistant HIV-1 in Amsterdam
Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, Berkhout B, Coutinho R, Back NK. Municipal Health Service Amsterdam, The Netherlands.
AIDS. 2004 Jul 23;18(11):1571-7.
Link naar publicatie

Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.
May M, Royston P, Egger M, Justice AC, Sterne JA; ART Cohort Collaboration.
Stat Med. 2004 Aug 15;23(15):2375-98.
Link naar publicatie

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
Van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM.
HIV Med. 2004 Mar;5(2):74-81.
Link naar publicatie

Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects
Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME. Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5.
Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME.
Link naar publicatie
Article in Dutch

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD,
Pradier C, Reiss P; D:A:D Study Group.
J Infect Dis. 2004 Mar 15;189(6):1056-74. Epub 2004 Mar 2.
Link naar publicatie

Virologic and Immunologic Response to Highly Active Antiretroviral Therapy in Indigenous and Nonindigenous HIV-1-Infected Patients in The Netherlands.
Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.
J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-950
Link naar publicatie

 

2003

 

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.
AIDS. 2003 May 23;17(8):1179-93.
Link naar publicatie

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.
Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. University Hospital Rotterdam, Dijkzigt, Rotterdam, The Netherlands.
AIDS. 2003 Jul;17 Suppl 3:S55-61
Link naar publicatie

Combination antiretroviral therapy and the risk of myocardial infarction.
Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD;
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.
N Engl J Med. 2003 Nov 20;349(21):1993-2003.
Link naar publicatie
Erratum in: N Engl J Med. 2004 Feb 26;350(9):955. Comment in: N Engl J Med. 2003 Nov 20;349(21):2065-7. Author reply N Engl J Med. 2004 Feb 12;350(7):730-2; author reply 730-2.

Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and Univ
Lancet. 2003 Jul 5;362(9377):22-9.
Link naar publicatie

HIV en AIDS in Nederland.
Op de Coul EL, Van Valkengoed I, Van Sighem AI, De Wolf F, Van der Laar MJW.
Rijksinstituut voor Volksgezondheid en Milieu; 2003
Link naar publicatie

Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study.
Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD; DAD Study Group.
HIV Med. 2003 Jan;4(1):1-10.
Link naar publicatie

Mortality and progression to AIDS after starting highly active antiretroviral therapy.
Van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group. HIV Monitoring Foundation, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands.
AIDS. 2003 Oct 17;17(15):2227-36.
Link naar publicatie
Comment in AIDS. 2003 Oct 17;17(15):2259-60.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort
Collaboration. D
Lancet. 2003 Aug 30;362(9385):679-86.
Link naar publicatie

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J; ATHENA Cohort Study Group. Department of Clinical Pharmacy, University Medical Centre, Nijmegen, the Netherlands.
AIDS. 2003 May 23;17(8):1157-65.
Link naar publicatie

Toenemend aantal allochtonen met HIV en aids in Nederland.
Op de Coul ELM, Van de Laar MJW, Van Valkengoed IGM, Van Sighem AI, De Wolf F.Infectieziekten Bulletin jaargang 14, nummer 12, 2003 (pagina 412-413).
Link naar publicatie

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME, Lange JM; ATHENA Study Group.
Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands.
Ther Drug Monit. 2003 Feb;25(1):73-80.
Link naar publicatie

Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group. Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University Co
AIDS. 2003 Aug 15;17(12):1741-51.
Link naar publicatie

 

2002

 

A Bayesian approach to parameter estimation in HIV dynamical models.
Putter H, Heisterkamp SH, Lange JM, de Wolf F. Department of Medical Statistics, Leiden University Medical Center, University of Leiden, P.O. Box 9604, 2300 RC Leiden, The Netherlands.
Stat Med. 2002 Aug 15;21(15):2199-214.
Link naar publicatie

Antigen-driven T-cell turnover
Fraser C, Ferguson NM, De Wolf F, Ghani AC, Garnett GP, Anderson RM. Department of Infectious Disease Epidemiology, Imperial College of Science, Technology and Medicine, St Mary's Campus, Norfolk Place, Paddington, London W21PG, UK.
J Theor Biol. 2002 Nov 21;219(2):177-92.
Link naar publicatie

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P, Brinkman K; ATHENA Study Group. The Pharmaco-Epidemiology Unit, Departments of Internal Medicine, and Epidemiology & Biostatistics, Er
AIDS. 2002 Mar 29;16(5):737-45.
Link naar publicatie

Full adherence to HAART: is it really necessary?
Arch Int Med, 2002; Apr 22: Vol 162, no 8:944-955.
Link naar publicatie

Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
Van Praag RM, Wit FW, Jurriaans S, de Wolf F, Prins JM, Lange JM. NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, The Netherlands
AIDS. 2002 Mar 29;16(5):719-25.
Link naar publicatie
Erratum in AIDS 2002 May 24;16(8):1199

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.
Dieleman JP, Sturkenboom MC, Wit FW, Jambroes M, Mulder JW, Ten Veen JH, Juttmann J, Stricker BH, Lange JM, Van Der Ende ME; AIDS Therapy Evaluation, The Netherlands Study Group (ATHENA). Pharmaco-Epidemiology Unit, and Departments of Epidemiology and Bio
J Infect Dis. 2002 May 1;185(9):1261-8. Epub 2002 Apr 16.
Link naar publicatie

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Departme
Lancet. 2002 Jul 13;360(9327):119-29.
Link naar publicatie
Erratum in Lancet 2002 Oct 12;360(9340):1178.
Pagina met onderzoek

Pros and cons of therapeutic drug monitoring of antiretroviral agents.
Burger DM, Aarnoutse RE, Hugen PW. Department of Clinical Pharmacy, University Medical Centre Nijmegen, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands.
Curr Opin Infect Dis. 2002 Feb;15(1):17-22.
Link naar publicatie

Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort.
Dieleman JP, Sturkenboom MC, Jambroes M, Gyssens IC, Weverling GJ, ten Veen JH, Schrey G, Reiss P, Stricker BH; Athena Study Group. Pharmaco-Epidemiology Unit, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
Arch Intern Med. 2002 Jul 8;162(13):1493-501.
Link naar publicatie

Viral replication under combination antiretroviral therapy: a comparison of four different regimens.
Ghani AC, Ferguson NM, Fraser C, Donnelly CA, Danner S, Reiss P, Lange J, Goudsmit J, Anderson RM, De Wolf F. Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK.
J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):167-76.
Link naar publicatie

 

2001

 

A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP, Prins JM, van der Poll T, ten Veen JH, Mulder JW, Meenhorst PL, Blok WL, van der Meer JT, Reiss P, Lange JM. Department of Clinical Pharmacy, University Medical Centre Nijmegen, The Netherlands.
J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):218-24.
Link naar publicatie 
 
Discontinuation of secondary prophylaxis against pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy.
Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, d'Arminio Monforte A, Schneider MME, Lundgren JD.
N Engl J Med. 2001; Jan 18: Vol 344:168-174.
Link naar publicatie 
 
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Foudraine NA, Jurriaans S, Weverling GJ, Burger DM, Hoetelmans RM, Roos MT, Maas J, Miedema F, Reiss P, Portegies P, de Wolf F, Lange JM. Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands.
Antivir Ther. 2001 Mar;6(1):55-62.
Link naar publicatie 
 
HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy.
Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F; Kliniek en Virologie van het ATHENA-project. Afd. Klinische Epidemiologie en Biostati
Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1591-7.
Link naar publicatie 
 
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project. Department of Medical Psychology (J4-
Arch Intern Med. 2001 Sep 10;161(16):1962-8.
Link naar publicatie
Comment in Arch Intern Med. 2002 Apr 22;162(8):944-5; author reply 945. Arch Intern Med. 2002 May 27;162(10):1197; author reply 1197-8. 

OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.
Van Praag RM, Prins JM, Roos MT, Schellekens PT, Ten Berge IJ, Yong SL, Schuitemaker H, Eerenberg AJ, Jurriaans S, de Wolf F, Fox CH, Goudsmit J, Miedema F, Lange JM. Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands J Clin Immunol. 2001 May;21(3):218-26.
Link naar publicatie 
 
Surrogate markers for disease progression in treated HIV infection.
Ghani AC, de Wolf F, Ferguson NM, Donnelly CA, Coutinho R, Miedema F, Goudsmit J, Anderson RM. Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College School of Science, Technology, and Medicine, London, UK.
Link naar publicatie 
 
The impact of immigration on env HIV-1 subtype distribution among heterosexuals in the Netherlands: influx of subtype B and non-B strains.
Op de Coul EL, Coutinho RA, van der Schoot A, van Doornum GJ, Lukashov VV, Goudsmit J, Cornelissen M; Dutch HIV-1 Subtype Surveillance. Department of Infectious Diseases Epidemiology, National Institute for Public Health and the Environment, Bilthoven, Th
AIDS. 2001 Nov 23;15(17):2277-86.
Link naar publicatie 
 
The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications.
Fraser C, Ferguson NM, de Wolf F, Anderson RM. Department of Infectious Disease Epidemiology, Imperial College of Science, Technology and Medicine, London, UK.
Proc R Soc Lond B Biol Sci. 2001 Oct 22;268(1481):2085-95
Link naar publicatie 

 

 
 

Stichting HIV Monitoring

Stichting HIV Monitoring (SHM) levert een belangrijke en noodzakelijke bijdrage aan de zorg voor mensen met hiv in Nederland. Door middel van het verzamelen en bewerken van gecodeerde data van hiv-positieve personen uit het hele land draagt ons monitor-onderzoek structureel bij aan de kennis over hiv en stelt het behandelend artsen in staat om de zorg voor hun patiënten continu te verbeteren. Ons jaarlijkse Monitoring Report geeft waardevolle input voor het ontwikkelen van hiv-zorg en preventiebeleid in Nederland en binnen de Europese Unie.

Bezoekadres

Nicolaes Tulphuis
Tafelbergweg 51
1105 BD Amsterdam

Postadres

Academisch Medisch Centrum
Universiteit van Amsterdam
Meibergdreef 9 1105 AZ Amsterdam

© Stichting HIV Monitoring  | Disclaimer  | Colofon